149 related articles for article (PubMed ID: 37030091)
1. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
[TBL] [Abstract][Full Text] [Related]
5. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
7. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
Xiang S; Wang J; Huang H; Wang Z; Song X; Zhou Y; Jin F; He X; Zhang ZM; Tu Z; Ding K; Zhang Z; Lu X
Eur J Med Chem; 2023 Jan; 245(Pt 1):114899. PubMed ID: 36410169
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
[TBL] [Abstract][Full Text] [Related]
9. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
11. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors.
Wu T; Zhang C; Lv R; Qin Q; Liu N; Yin W; Wang R; Sun Y; Wang X; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Nov; 223():113627. PubMed ID: 34171657
[TBL] [Abstract][Full Text] [Related]
13. Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
Wu T; Qin Q; Liu N; Zhang C; Lv R; Yin W; Sun Y; Sun Y; Wang R; Zhao D; Cheng M
Eur J Med Chem; 2022 Feb; 230():114096. PubMed ID: 35007864
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
[TBL] [Abstract][Full Text] [Related]
15. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
Panchal I; Tripathi RKP; Parmar K; Yadav MR
Curr Top Med Chem; 2024; 24(1):3-30. PubMed ID: 38058091
[TBL] [Abstract][Full Text] [Related]
17. Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
Mei LC; Zhuo LS; Xu HC; Huang W; Hao GF; Yang GF
Eur J Med Chem; 2022 Jul; 237():114406. PubMed ID: 35486994
[TBL] [Abstract][Full Text] [Related]
18. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]